Terns Pharmaceuticals Announces Completion and Positive Results from Phase I Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH

Terns Pharmaceuticals, Inc., has announced positive results from its completed Phase I single ascending dose and multiple ascending dose study of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, being developed for the treatment of non-alcoholic steatohepatitis (NASH).
[Terns Pharmaceuticals]
Press Release

Continue reading “Terns Pharmaceuticals Announces Completion and Positive Results from Phase I Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH”

Bookmark

No account yet? Register

0
Share

ORTIKOS, the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S.

Ferring Pharmaceuticals Inc. announced the launch of ORTIKOS™ in the United States, which was approved as the only once-daily treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon, in patients 8 years of age and older, and maintenance of clinical remission in adults involving the ileum and/or the ascending colon for up to three months.
[Ferring Pharmaceuticals (Businesswire, Inc.)]
Press Release

Continue reading “ORTIKOS, the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S.”

Bookmark

No account yet? Register

0
Share

Veru Receives Positive Input from FDA on Phase III Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

Veru Inc. announced that it has received regulatory clarity from the FDA on the pivotal Phase III trial design for VERU-111—its oral, first-in-class, novel alpha and beta tubulin targeting drug candidate being evaluated for the treatment of metastatic castration and novel androgen-blocking agent resistant prostate cancer.
[Veru Inc.]
Press Release

Continue reading “Veru Receives Positive Input from FDA on Phase III Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer”

Bookmark

No account yet? Register

0
Share

Britta Will, Ph.D., Wins Pershing Square Sohn Prize for Cancer Research

Britta Will, Ph.D., assistant professor of medicine and of cell biology at Albert Einstein College of Medicine, has won a 2020 Pershing Square Sohn Prize for Young Investigators in Cancer Research. Dr. Will is one of seven New York City area-based scientists to receive the prestigious award, which provides $600,000 over three years for innovative basic science cancer research.
[Albert Einstein College of Medicine]
Press Release

Continue reading “Britta Will, Ph.D., Wins Pershing Square Sohn Prize for Cancer Research”

Bookmark

No account yet? Register

0
Share

China’s Coronavirus Vaccines Are Leaping Ahead – But Face Challenges as Virus Wanes

Chinese companies are at the forefront of global efforts to create a vaccine for the coronavirus, with more than half a dozen candidates in clinical development. Last week, Tianjin-based CanSino Biologics published results from an early-stage clinical trial showing that its vaccine is safe and can trigger an immune response. Yet the companies could face difficulty as they try to push vaccines through Phase III trials, a crucial stage of testing that is needed to prove efficacy and secure approval from regulators.
[Nature News]
Press Release

Continue reading “China’s Coronavirus Vaccines Are Leaping Ahead – But Face Challenges as Virus Wanes”

Bookmark

No account yet? Register

0
Share

European Commission Grants Marketing Authorisation for World’s First Subcutaneous Formulation of Infliximab, Remsima® SC, for an Additional Five Indications including for Use in Inflammatory Bowel Disease and Ankylosing Spondylitis

Celltrion Healthcare announced that the European Commission has granted marketing authorisation for Remsima® subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
[Celltrion Healthcare ]
Press Release

Continue reading “European Commission Grants Marketing Authorisation for World’s First Subcutaneous Formulation of Infliximab, Remsima® SC, for an Additional Five Indications including for Use in Inflammatory Bowel Disease and Ankylosing Spondylitis”

Bookmark

No account yet? Register

0
Share

Emerald Health Pharmaceuticals Begins Enrollment in Phase IIa Study of EHP-101 for the Treatment of Systemic Sclerosis

Emerald Health Pharmaceuticals, Inc. has begun enrollment and has dosed its first patients with diffuse cutaneous systemic sclerosis in its Phase IIa clinical study of its lead product candidate, EHP-101, an oral formulation of a patented new chemical entity derived from cannabidiol.
[Emerald Health Pharmaceuticals, Inc.]
Press Release

Continue reading “Emerald Health Pharmaceuticals Begins Enrollment in Phase IIa Study of EHP-101 for the Treatment of Systemic Sclerosis”

Bookmark

No account yet? Register

0
Share

China’s Coronavirus Vaccines Are Leaping Ahead – but Face Challenges as Virus Wanes

Chinese companies are at the forefront of global efforts to create a vaccine for the coronavirus, with more than half a dozen candidates in clinical development. Yet the companies could face difficulty as they try to push vaccines through phase III trials, a crucial stage of testing that is needed to prove efficacy and secure approval from regulators.
[Nature News]
Press Release

Continue reading “China’s Coronavirus Vaccines Are Leaping Ahead – but Face Challenges as Virus Wanes”

Bookmark

No account yet? Register

0
Share

‘A Huge Experiment’: How the World Made So Much Progress on a COVID-19 Vaccine So Fast

The astonishing pace of vaccine progress is also a consequence of the virus itself: It is, scientifically speaking, an easier target for potential vaccines than other pathogens, and a prime candidate for cutting-edge vaccine platforms new to scientists’ toolkits.
[STAT News]
Press Release

Continue reading “‘A Huge Experiment’: How the World Made So Much Progress on a COVID-19 Vaccine So Fast”

Bookmark

No account yet? Register

0
Share

Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, Trastuzumab Biosimilar

Shanghai Henlius Biotech, Inc. and Accord Healthcare Limited jointly announced the European Commission has approved Zercepac ® for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer.
[Henlius]
Press Release

Continue reading “Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, Trastuzumab Biosimilar”

Bookmark

No account yet? Register

0
Share

Strategic Alliance a Shot in the Arm for Stem Cell Commercialization Efforts

Several Canadian-made cell therapies will take a major step closer to the clinic thanks to a new collaboration between the Ontario Institute for Regenerative Medicine and the Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine.
[Ontario Institute for Regenerative Medicine]
Press Release

Continue reading “Strategic Alliance a Shot in the Arm for Stem Cell Commercialization Efforts”

Bookmark

No account yet? Register

0
Share

Cleave Therapeutics Announces Commencement of a Phase I Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Cleave Therapeutics, Inc. announced that the first patient has been dosed with CB-5339 in a Phase I clinical trial of patients with relapsed/refractory AML or relapsed/refractory intermediate or high-risk MDS.
[Cleave Therapeutics, Inc.]
Press Release

Continue reading “Cleave Therapeutics Announces Commencement of a Phase I Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)”

Bookmark

No account yet? Register

0
Share
Share